Cellular therapy clinical trial results in relapsed/refractory Hodgkin lymphoma
| Therapy . | Lymphodepletion . | Patients . | Efficacy . | Toxicity . | Reference . |
|---|---|---|---|---|---|
| EBV-specific T cells | None | 14 (EBV+ HL) | Active disease (11 patients): 18% CR, 9% PR, 45% SD Some remissions up to 40 mo | Flu-like symptoms (14%) | Bollard et al.62 |
| LMP 1/2-specific T cells | None | 50 (EBV+ lymphoma) 25 HL | Active disease (21 patients): 52% CR, 9.5% PR 2-y EFS: 50% Adjuvant therapy (29 patients): 28 patients in CR at median 3.1 y of follow-up | No DLT | Bollard et al.54 |
| LMP 1/2 specific T cells with DNRII | None | 8 (EBV+ HL) | Active disease (7 patients): 29% CR, 14% PR, 57% SD 2 patients with ongoing response >4 y | No DLT | Bollard et al.55 |
| Multiantigen targeted T Cells | None | 32 (14 HL, 7 with active disease) | Active disease (7 patients): 29% durable CR (>3 y) | No DLT | Vasileiou et al.56 |
| Multiantigen targeted T cells with nivolumab | None | 10 (6 received nivolumab) | Active disease (8 patients): 13% CR, 88% SD 38% in SD at 1 y | No DLT | Dave et al.57 |
| CD30 CAR-T cells | Flu/Cy; Gem/mustargen/Cy; nab-paclitaxel/Cy | 18 | 39% PR, 33% SD Median PFS 6 mo | Grade 1-2 febrile syndrome within 24 h (100%) Rash (11%) | Wang et al.63 |
| CD30 CAR-T cells | None | 9 (7 HL) | HL patients: 29% CR 1 durable CR >2.5 y | No DLT | Ramos et al.64 |
| CD30 CAR-T Cells | Benda; Flu/Benda; Flu/Cy | 41 | ORR 62%; for patients with flu: ORR 72% with 59% CR; 1-y PFS: 36% | Gr1 CRS (24%) Rash (48%) | Ramos et al.46 |
| CD30 CAR-T cells with PD-1 inhibitor | Flu/Cy | 12 (9 HL); 8 had prior CPI | ORR 92%; 50% CR Median follow-up 21.5 mo; PFS 45% | CRS (25%) Gr3 CRS (8%) | Sang et al.51 |
| CD30 CAR-T cells | Flu/Benda | 15 | ORR 73.3%; 60% CR Median PFS 6.5 mo | Gr1 CRS (7%) | Ahmed et al.47 |
| CD30 CAR-T cells (HSP-CAR30) | Flu/Benda | 10 (8 HL) | ORR 100% with 50% CR Mean PFS: 235 d All CRs maintained | Gr1 CRS (60%) Rash (40%) | Caballero Gonzalez et al.50 |
| CD30.CCR4 CAR-T cells | Flu/Benda | 12 (10 HL) | HL: 70% CR, 30% PR Median follow-up 8.5 mo; mPFS for HL not reached | CRS (33%) Gr1 CRS (17%) Gr2 CRS (17%) | Grover et al.49 |
| CD30.CAR—modified EBV-specific T cells (Allogeneic) | Flu/Cy | 16 | ORR 75% (38% CR, 38% PR) | Gr1 CRS (31%) | Ramos et al.58 |
| AFM13 + NK cells | Flu/Cy | 30 (28 HL) | ORR 97% with 67% CR EFS at 8 mo: 57% | Infusion reactions with AFM13 (37%) Gr3 infusion reaction (3%) Gr2 infusion reaction (33%) | Nieto et al.60 |
| Therapy . | Lymphodepletion . | Patients . | Efficacy . | Toxicity . | Reference . |
|---|---|---|---|---|---|
| EBV-specific T cells | None | 14 (EBV+ HL) | Active disease (11 patients): 18% CR, 9% PR, 45% SD Some remissions up to 40 mo | Flu-like symptoms (14%) | Bollard et al.62 |
| LMP 1/2-specific T cells | None | 50 (EBV+ lymphoma) 25 HL | Active disease (21 patients): 52% CR, 9.5% PR 2-y EFS: 50% Adjuvant therapy (29 patients): 28 patients in CR at median 3.1 y of follow-up | No DLT | Bollard et al.54 |
| LMP 1/2 specific T cells with DNRII | None | 8 (EBV+ HL) | Active disease (7 patients): 29% CR, 14% PR, 57% SD 2 patients with ongoing response >4 y | No DLT | Bollard et al.55 |
| Multiantigen targeted T Cells | None | 32 (14 HL, 7 with active disease) | Active disease (7 patients): 29% durable CR (>3 y) | No DLT | Vasileiou et al.56 |
| Multiantigen targeted T cells with nivolumab | None | 10 (6 received nivolumab) | Active disease (8 patients): 13% CR, 88% SD 38% in SD at 1 y | No DLT | Dave et al.57 |
| CD30 CAR-T cells | Flu/Cy; Gem/mustargen/Cy; nab-paclitaxel/Cy | 18 | 39% PR, 33% SD Median PFS 6 mo | Grade 1-2 febrile syndrome within 24 h (100%) Rash (11%) | Wang et al.63 |
| CD30 CAR-T cells | None | 9 (7 HL) | HL patients: 29% CR 1 durable CR >2.5 y | No DLT | Ramos et al.64 |
| CD30 CAR-T Cells | Benda; Flu/Benda; Flu/Cy | 41 | ORR 62%; for patients with flu: ORR 72% with 59% CR; 1-y PFS: 36% | Gr1 CRS (24%) Rash (48%) | Ramos et al.46 |
| CD30 CAR-T cells with PD-1 inhibitor | Flu/Cy | 12 (9 HL); 8 had prior CPI | ORR 92%; 50% CR Median follow-up 21.5 mo; PFS 45% | CRS (25%) Gr3 CRS (8%) | Sang et al.51 |
| CD30 CAR-T cells | Flu/Benda | 15 | ORR 73.3%; 60% CR Median PFS 6.5 mo | Gr1 CRS (7%) | Ahmed et al.47 |
| CD30 CAR-T cells (HSP-CAR30) | Flu/Benda | 10 (8 HL) | ORR 100% with 50% CR Mean PFS: 235 d All CRs maintained | Gr1 CRS (60%) Rash (40%) | Caballero Gonzalez et al.50 |
| CD30.CCR4 CAR-T cells | Flu/Benda | 12 (10 HL) | HL: 70% CR, 30% PR Median follow-up 8.5 mo; mPFS for HL not reached | CRS (33%) Gr1 CRS (17%) Gr2 CRS (17%) | Grover et al.49 |
| CD30.CAR—modified EBV-specific T cells (Allogeneic) | Flu/Cy | 16 | ORR 75% (38% CR, 38% PR) | Gr1 CRS (31%) | Ramos et al.58 |
| AFM13 + NK cells | Flu/Cy | 30 (28 HL) | ORR 97% with 67% CR EFS at 8 mo: 57% | Infusion reactions with AFM13 (37%) Gr3 infusion reaction (3%) Gr2 infusion reaction (33%) | Nieto et al.60 |
Benda, bendamustine; CRS, cytokine release syndrome; Cy, cyclophosphamide; DLT, dose-limiting toxicity; DNRII, dominant-negative TGF-β receptor type 2; Flu, fludarabine; Gem, gemcitabine; Gr, grade; HL, Hodgkin lymphoma; LMP, latency membrane protein; mPFS, median progression free survival; SD, stable disease.